ICT 111

Drug Profile

ICT 111

Alternative Names: Cancer stem cell antigen vaccine; ICT-111

Latest Information Update: 16 Dec 2013

Price : $50

At a glance

  • Originator ImmunoCellular Therapeutics
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants; Stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Glioblastoma

Most Recent Events

  • 03 Dec 2013 Discontinued - Preclinical for Glioblastoma in USA prior to December 2013 (Parenteral)
  • 27 May 2010 Pharmacodynamics data from a preclinical trial in Glioblastoma released by ImmunoCellular Therapeutics
  • 23 May 2008 Preclinical trials in Glioblastoma in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top